Wei-Xiang Sin

Wei-Xiang Sin

Auto-generated profile, based on publicly available information

Wei-Xiang Sin

Critical Analytics for Manufacturing Personalized-Medicine (CAMP), Singapore-MIT Alliance for Research and Technology Centre (SMART), Singapore

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2024 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
WSWei-Xiang Sin
Wei-Xiang Sin
NJN. Suhas Jagannathan
N. Suhas Jagannathan
DTDenise Bei Lin Teo
Denise Bei Lin Teo
FKFaris Kairi
Faris Kairi
SFShin Yie Fong
Shin Yie Fong
MBMichael E. Birnbaum
Michael E. Birnbaum

17 October 2023 in Microbiology Spectrum
Verified
Journal Article
Open access
JSJames P. B. Strutt
James P. B. Strutt
MNMeenubharathi Natarajan
Meenubharathi Natarajan
ELElizabeth Lee
Elizabeth Lee
DTDenise Bei Lin Teo
Denise Bei Lin Teo
WSWei-Xiang Sin
Wei-Xiang Sin
SSStacy L. Springs
Stacy L. Springs
Assuring that cell therapy products are safe before releasing them for use in patients is critical. Currently, compendial sterility testing for bacteria and fungi can take 7–14 days. The goal of this work was to develop a rapid untargeted approach for the sensitive detection of microbial contaminants at low abundance from low volume samples during the manufacturing process of cell therapies. We developed a long-read sequencing methodology using Oxford Nanopore Technologies MinION platform with 16S and 18S amplicon sequencing to detect USP organisms and other microbial species. Reads are classified metagenomically to predict the microbial species. We used an extreme gradient boosting machine learning algorithm (XGBoost) to first assess if a sample is contaminated, and second, determine whether the predicted contaminant is correctly classified or misclassified. The model was used to make a final decision on the sterility status of the input sample. An optimized experimental and bioinformatics pipeline starting from spiked species through to sequenced reads allowed for the detection of microbial samples at 10 colony-forming units (CFU)/mL using metagenomic classification. Machine learning can be coupled with long-read sequencing to detect and identify sample sterility status and microbial species present in T-cell cultures, including the USP organisms to 10 CFU/mL. IMPORTANCE: This research presents a novel method for rapidly and accurately detecting microbial contaminants in cell therapy products, which is essential for ensuring patient safety. Traditional testing methods are time-consuming, taking 7–14 days, while our approach can significantly reduce this time. By combining advanced long-read nanopore sequencing techniques and machine learning, we can effectively identify the presence and types of microbial contaminants at low abundance levels. This breakthrough has the potential to improve the safety and efficiency of cell therapy manufacturing, leading to better patient outcomes and a more streamlined production process.

6 March 2023 in Blood
Verified
Journal Article
Open access
PDF file
CLChrissie K. Lim
Chrissie K. Lim
YZYoujia Zhong
Youjia Zhong
RHRichard Hopkins
Richard Hopkins
WSWei-Xiang Sin
Wei-Xiang Sin
BABijin Veonice Au
Bijin Veonice Au
JCJohn E Connolly
John E Connolly
Severe mosquito bite allergy (SMBA) is a manifestation of chronic active Epstein-Barr virus (CAEBV) infection defined by necrotic ulceration of the stings. CAEBV with SMBA has a high mortality rate as most patients eventually develop fulminant and refractory hemophagocytic lymphohistiocytosis (HLH). However, how self-resolving SMBA escalates to systemic lethal HLH remains unclear. Through comprehensive immune profiling of a SMBA patient with CAEBV and her healthy monozygotic twin, we found that both twins were seropositive for EBV but showed high discordance in their circulating natural killer (NK) cells. The patient's EBV-infected NK cells displayed memory-like properties, including low CD16, high CD226 and induction of enhanced IFNγ production by IL-2 or IL-12. Her leukocytes also produced high levels of IL-2 and IL-12 when stimulated with salivary gland extract (SGE) specifically from A. albopictus mosquitoes, connected again with hyperproduction of IFNγ by her NK cells. Strikingly, pharmacological inhibition of STAT3 suppressed the NK memory-associated cytokine axis of IFNγ, IL-2 and IL-12 that is generated by A. albopictus SGE stimulation. Altogether, this study shows that NK memory is promoted during CAEBV with SMBA by repeated cytokine restimulation leading up to lethal HLH, and proposes STAT3 as a therapeutic target to halt its progression.

7 April 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
WSWei-Xiang Sin
Wei-Xiang Sin
NJNarendra Suhas Jagannathan
Narendra Suhas Jagannathan
DTDenise Bei Lin Teo
Denise Bei Lin Teo
FKFaris Kairi
Faris Kairi
DSDedy Sandikin
Dedy Sandikin
MBMichael E. Birnbaum
Michael E. Birnbaum
While adoptive cell therapies have revolutionized cancer immunotherapy, current autologous chimeric antigen receptor (CAR) T cell manufacturing face challenges in scaling to meet patient demands. CAR T cell production still largely rely on fed-batch, manual, open processes that lack environmental monitoring and control, whereas most perfusion-based, automated, closed-system bioreactors currently suffer from large footprints and working volumes, thus hindering process development and scaling-out. Here, we present a means of conducting anti-CD19 CAR T cell culture-on-a-chip. We show that T cells can be activated, transduced, and expanded to densities exceeding 150 million cells/mL in a two-milliliter perfusion-capable microfluidic bioreactor, thus enabling the production of CAR T cells at clinical dose levels in a small footprint. Key functional attributes such as exhaustion phenotype and cytolytic function were comparable to T cells generated in a gas-permeable well. The process intensification and online analytics offered by the microbioreactor could facilitate high-throughput process optimization studies, as well as enable efficient scale-out of cell therapy manufacturing, while providing insights into the growth and metabolic state of the CAR T cells during ex vivo culture.

15 May 2025 in Cytotherapy
Verified
Journal Article
Closed access
KCKa-Wai Cheung
Ka-Wai Cheung
FKFaris Kairi
Faris Kairi
DTDenise Bei Lin Teo
Denise Bei Lin Teo
WSWei-Xiang Sin
Wei-Xiang Sin
YLYen Hoon Luah
Yen Hoon Luah
MBMichael E. Birnbaum
Michael E. Birnbaum

13 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
NJN. Suhas Jagannathan
N. Suhas Jagannathan
WSWei-Xiang Sin
Wei-Xiang Sin
DTDenise Bei Lin Teo
Denise Bei Lin Teo
FKFaris Kairi
Faris Kairi
YLYen Hoon Luah
Yen Hoon Luah
RRRajeev J. Ram
Rajeev J. Ram
Adoptive cell therapies such as CAR T cells have revolutionized cancer treatment and shown successes even with refractory cases of haematological malignancies. There is burgeoning interest in the optimization and improved manufacturing of cell therapy products. For CAR T cell therapy, enrichment of certain phenotypes of T cells in the infusion product have been correlated with improved long-term treatment outcomes. While metabolic control of T cell phenotypic fates has been demonstrated in some contexts, gaps still exist in our knowledge of how T cell metabolic dynamics early during CAR T manufacturing might affect critical quality attributes (CQAs) of the final product (e.g., differentiation/exhaustion/potency). We present a modelling framework that can perform real-time estimation of per-cell metabolic rates of T cells expanded ex vivo in a reactor. We validate our estimated rates using metabolic assays, show how average rates can be deconvoluted to rates of individual T cell phenotypes, and demonstrate applicability to different reactor types. Applying our tool to the expansion of both healthy and patient-derived cells in a perfusion-based microbioreactor, we offer proof-of-principle to show that correlations exist between early metabolic rates of T cells in culture and cellular attributes related to growth, differentiation and exhaustion of the final product. Given the biological variation that exists in the growth and dynamics of patient-derived cells in culture, such modelling contributes to the overarching goal of improving the consistency of cell therapy through Adaptive Process Control (APC).